Abstract
To identify and clarify definitions and methods of measuring cancer-related cognitive
impairment among prostate cancer patients treated with Androgen Deprivation Therapy (ADT)
and to assess the incidence and prevalence of cognitive impairment. A systematic review of
Medline, EMBASE, PubMed, PsycINFO and CINAHL up to December 2015 was undertaken
to identify English-language reviews. A total of twenty-eight reviews were identified
describing twenty primary studies. There were no studies of incidence. Reported prevalence
rates varied between 10 and 69%. Cognitive domains impaired by ADT included: verbal
memory, visuospatial ability and executive functions. Cognitive impairment was infrequently
defined and four definitions were reported. A variety of measures and methods were used to
assess cognitive function including neuropsychological tests, self-report measures and clinical
assessments. The finding that, often, one measure was used to assess more than one aspect of
cognition is likely to have contributed to imprecise estimates. There is a need to agree a
definition of cognitive impairment in the clinical epidemiology of cancer and to standardise
the selection of measures in order to aid accurate assessment and fair comparisons across
studies regarding the prevalence of cognitive impairment among prostate cancer patients
| Original language | English |
|---|---|
| Journal | European Journal of Cancer Care |
| Early online date | 07 Feb 2017 |
| DOIs | |
| Publication status | Early online date - 07 Feb 2017 |
Access to Document
- Cognitive impairment among prostate cancer patients: an overview of reviews
Copyright 2017 Wiley. This work is made available online in accordance with the publisher’s policies. Please refer to any applicable terms of use of the publisher.